Show simple item record

dc.contributor.authorAndersen, Jintana Bunpanen_US
dc.contributor.authorOwe, Jone Furulunden_US
dc.contributor.authorEngeland, Andersen_US
dc.contributor.authorGilhus, Nils Eriken_US
dc.date.accessioned2014-12-03T13:17:58Z
dc.date.available2014-12-03T13:17:58Z
dc.date.issued2014-04-09eng
dc.identifier.issn1351-5101
dc.identifier.urihttps://hdl.handle.net/1956/8819
dc.description.abstractBackground and purpose: Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods: All recipients of the MG-specific drug pyridostigmine 2004–2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. Results: Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives (1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8). Conclusions: Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity.en_US
dc.language.isoengeng
dc.publisherWileyeng
dc.relation.ispartof<a href="http://hdl.handle.net/1956/11708" target="blank">Epidemiology, comorbidity and clinical course of myasthenia gravis. A registry-based study</a>eng
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-NDeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/eng
dc.subjectCo-morbidityeng
dc.subjectDrug therapyeng
dc.subjectmyasthenia graviseng
dc.titleTotal drug treatment and comorbidity in myasthenia gravis: a population-based cohort studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2014 The Author(s)
dc.identifier.doihttps://doi.org/10.1111/ene.12439
dc.identifier.cristin1163664
dc.source.journalEuropean Journal of Neurology
dc.source.4021
dc.source.147
dc.source.pagenumber948-955


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND